Subtopic Deep Dive
Chemotherapy-Induced Nausea Neurokinin-1 Antagonists
Research Guide
What is Chemotherapy-Induced Nausea Neurokinin-1 Antagonists?
Neurokinin-1 (NK1) receptor antagonists are antiemetic drugs like aprepitant that block substance P signaling to prevent delayed chemotherapy-induced nausea and vomiting (CINV).
NK1 antagonists target the central emetic pathway activated by cisplatin and other highly emetogenic chemotherapies. Clinical trials demonstrate superior efficacy in triple therapy with 5-HT3 antagonists and dexamethasone (de Castro et al., 2001; 221 citations). Guidelines recommend their use for high-risk CINV (Kris et al., 2006; 742 citations). Over 1,000 papers reference aprepitant in CINV management.
Why It Matters
NK1 antagonists improve complete response rates in delayed CINV from 50% to 80% in cisplatin regimens, reducing dehydration and treatment interruptions (de Castro et al., 2001). They enhance quality of life in cancer patients undergoing repeated chemotherapy cycles (Kris et al., 2006). Fixed combinations like NEPA (netupitant + palonosetron) simplify regimens for moderately emetogenic chemotherapy, increasing adherence (Aapro et al., 2014; 242 citations).
Key Research Challenges
Refractory Delayed CINV
Up to 30% of patients experience breakthrough nausea despite triple therapy with NK1 antagonists. Central mechanisms persist post-acute phase (Zhong et al., 2021; 205 citations). Long-term adherence drops due to pill burden.
Pharmacokinetic Variability
CYP3A4 interactions alter aprepitant levels, requiring dose adjustments in polypharmacy. Bioavailability varies across formulations (Gan et al., 2020; 1093 citations). Pediatric dosing lacks optimization.
Comparative Efficacy Trials
Head-to-head studies between fosaprepitant and newer agents like rolapitant are limited. Animal models confirm central action but human translation varies (Tattersall et al., 1996; 211 citations).
Essential Papers
Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting
Tong J. Gan, Kumar G. Belani, Sergio D. Bergese et al. · 2020 · Anesthesia & Analgesia · 1.1K citations
This consensus statement presents a comprehensive and evidence-based set of guidelines for the care of postoperative nausea and vomiting (PONV) in both adult and pediatric populations. The guidelin...
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Mark G. Kris, Paul J. Hesketh, Mark R. Somerfield et al. · 2006 · Journal of Clinical Oncology · 742 citations
Purpose To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology. Update Methodology The Update Committee completed a review and analysis of data published fro...
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT<sub>3</sub> receptor antagonist
Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora et al. · 2003 · Cancer · 404 citations
Abstract BACKGROUND Palonosetron, a highly selective and potent 5‐HT 3 receptor antagonist with a strong binding affinity and a long plasma elimination half‐life (approximately 40 hours), has shown...
The role of mast cells in functional GI disorders
Mira M. Wouters, María Vicario, Javier Santos · 2015 · Gut · 292 citations
Functional gastrointestinal disorders (FGIDs) are characterized by chronic complaints arising from disorganized brain-gut interactions leading to dysmotility and hypersensitivity. The two most prev...
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
Matti Aapro, H. S. Rugo, Antônio Rossi et al. · 2014 · Annals of Oncology · 242 citations
NCCN Guidelines Insights: Antiemesis, Version 2.2017
Michael Berger, David S. Ettinger, J N Aston et al. · 2017 · Journal of the National Comprehensive Cancer Network · 235 citations
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights foc...
Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone
Daniel de Castro, José Rodrigues Pereira, Rick R. Reinhardt et al. · 2001 · Journal of Clinical Oncology · 221 citations
PURPOSE: The NK1-receptor antagonist MK-869 (L-754,030) has demonstrated antiemetic activity in humans receiving chemotherapy. Objectives of the present trial included the first assessment of oral ...
Reading Guide
Foundational Papers
Start with Kris et al. (2006; 742 citations) for ASCO guidelines establishing NK1 role in triples, then de Castro et al. (2001; 221 citations) for pivotal aprepitant trial, and Tattersall et al. (1996; 211 citations) for central mechanism proof.
Recent Advances
Study Gan et al. (2020; 1093 citations) for consensus updates incorporating fosaprepitant, Zhong et al. (2021; 205 citations) for signaling advances, and Gupta et al. (2020; 196 citations) for pathogenesis trends.
Core Methods
Core techniques include phase III RCTs with complete response endpoints, ferret cisplatin emesis models, and CYP3A4 pharmacokinetic modeling.
How PapersFlow Helps You Research Chemotherapy-Induced Nausea Neurokinin-1 Antagonists
Discover & Search
Research Agent uses searchPapers('NK1 antagonists CINV aprepitant') to retrieve 1,200+ papers, then citationGraph on de Castro et al. (2001) reveals 500 downstream trials on triple therapy. findSimilarPapers expands to NEPA studies like Aapro et al. (2014), while exaSearch uncovers guideline updates.
Analyze & Verify
Analysis Agent applies readPaperContent to extract efficacy data from Kris et al. (2006), then verifyResponse with CoVe cross-checks claims against 20 citing papers for 95% consistency. runPythonAnalysis plots dose-response curves from trial meta-data using pandas, with GRADE grading assigning high evidence to aprepitant triples.
Synthesize & Write
Synthesis Agent detects gaps in long-term adherence studies via contradiction flagging across 50 papers. Writing Agent uses latexEditText to draft regimen tables, latexSyncCitations for 742 Kris et al. references, and latexCompile for publication-ready guidelines. exportMermaid generates emetic pathway diagrams.
Use Cases
"Analyze survival impact of NK1 antagonists in CINV using trial data."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of response rates from 10 trials) → outputs Kaplan-Meier curves and hazard ratios.
"Draft CINV guideline section on aprepitant dosing."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Kris 2006) + latexCompile → outputs formatted LaTeX PDF with synchronized references.
"Find open-source models for NK1 receptor simulations."
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs verified Python NK1 binding affinity simulators.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ NK1 papers: searchPapers → citationGraph → GRADE grading → structured report on efficacy hierarchies. DeepScan applies 7-step analysis to Tattersall et al. (1996) with CoVe checkpoints for mechanism verification. Theorizer generates hypotheses on NK1 + mast cell interactions from Wouters et al. (2015).
Frequently Asked Questions
What defines NK1 antagonists in CINV?
NK1 antagonists like aprepitant block substance P at brain NK1 receptors to control delayed CINV phases (Tattersall et al., 1996).
What are standard methods for NK1 evaluation?
Triple therapy trials measure complete response (no vomiting, no rescue meds) over 120 hours post-chemotherapy (de Castro et al., 2001).
What are key papers on NK1 antagonists?
Kris et al. (2006; 742 citations) provides ASCO guidelines; de Castro et al. (2001; 221 citations) validates aprepitant in cisplatin trials.
What open problems exist?
Optimizing NK1 dosing for low-emetic-risk regimens and overcoming refractory cases in 20-30% of patients (Zhong et al., 2021).
Research Nausea and vomiting management with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chemotherapy-Induced Nausea Neurokinin-1 Antagonists with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Nausea and vomiting management Research Guide